Neurontin Capsule 100 mg (Gabapentin)

Adult dose

Monotherapy and adjunctive therapy for patients with epilepsy aged 13 years and older: To achieve a maintenance dose of 900 mg/day as gabapentin, titrate the dose over the first 3 days of treatment as follows. Day 1: Administer one 300 mg capsule of this product once daily, or one 100 mg capsule of this product 3 times daily (gabapentin 300 mg/day) Day 2: Administer one 300 mg capsule of this product twice daily, or two 100 mg capsules of this product 3 times daily (gabapentin 600 mg/day) From Day 3 onward: Administer one 300 mg capsule of this product 3 times daily, or three 100 mg capsules of this product 3 times daily (gabapentin 900 mg/day) Alternatively, as an initial dose, one 300 mg capsule of this product may be administered 3 times daily (gabapentin 900 mg/day). The dose may be increased to 1,200 mg/day as gabapentin, and the total daily dose must not exceed 2,400 mg as gabapentin. (There are insufficient data on the safety and efficacy of doses exceeding 2,400 mg/day as gabapentin.) Adults (18 years and older) with neuropathic pain: To achieve a maintenance dose of 900 mg/day as gabapentin, titrate the dose over the first 3 days of treatment as follows. Day 1: Administer one 300 mg capsule of this product once daily, or one 100 mg capsule of this product 3 times daily (gabapentin 300 mg/day) Day 2: Administer one 300 mg capsule of this product twice daily, or two 100 mg capsules of this product 3 times daily (gabapentin 600 mg/day) From Day 3 onward: Administer one 300 mg capsule of this product 3 times daily, or three 100 mg capsules of this product 3 times daily (gabapentin 900 mg/day) Alternatively, as an initial dose, one 300 mg capsule of this product may be administered 3 times daily (gabapentin 900 mg/day). If necessary, the dose may be increased to 1,800 mg/day as gabapentin within one week, and the total daily dose must not exceed 3,600 mg as gabapentin. The total daily dose of this product should be divided into 3 doses. Debilitated patients: In debilitated patients with low body weight or patients after transplantation, the gabapentin dose should be increased in 100 mg increments. Elderly patients: Dosage adjustment may be necessary due to age-related decline in renal function (see table). Patients with renal impairment (creatinine clearance ≤80 mL/min) or patients receiving hemodialysis: Dosage adjustment is required based on the following table. Renal function, creatinine clearance (mL/min) ≥80: Total daily dosea (mg/day) 900∼2,400 Renal function, creatinine clearance (mL/min) 50∼79: Total daily dosea (mg/day) 600∼1,800 Renal function, creatinine clearance (mL/min) 30∼49: Total daily dosea (mg/day) 300∼900 Renal function, creatinine clearance (mL/min) 15∼29: Total daily dosea (mg/day) 150b∼600 Renal function, creatinine clearance (mL/min) <15: Total daily dosea (mg/day) 150b∼300 a: The total daily dose should be divided into 3 doses. b: Administer 3 × 100 mg every 2 days. In patients with creatinine clearance less than 15 mL/min, the dose should be reduced in proportion to the creatinine clearance. Dosage in hemodialysis patients Initial dose: 300∼400 mg of gabapentin is recommended. Maintenance dose: Administer 200∼300 mg of gabapentin after 4 hours of hemodialysis; do not administer this product on days when hemodialysis is not performed. This product should be swallowed whole with sufficient fluid and may be taken with or without food. When administered 3 times daily, ensure that the interval between doses does not exceed 12 hours to prevent recurrence of seizures. If a dose of this product is missed (when more than 12 hours have elapsed since the last dose), the physician should decide whether an additional dose should be administered to make up for it. When used concomitantly with antacids containing magnesium or aluminum, this product should be administered at least 2 hours after the antacid. This can substantially reduce the decrease in the bioavailability of this product. The duration of treatment with this product should depend on clinical need. Long-term treatment is generally required for epilepsy. Although there is no evidence of a rebound phenomenon (increased seizure frequency due to sudden discontinuation of treatment), sudden discontinuation of antiepileptic drugs in patients with epilepsy may cause status epilepticus. If treatment with this product is to be discontinued, or if it is to be used concomitantly with another antiepileptic drug, changes should be made gradually over at least 1 week. The safety and efficacy of treatment for neuropathic pain for more than 5 months have not been evaluated. To reduce the main adverse effects, such as somnolence, dizziness, fatigue, and ataxia, the first dose on Day 1 should be taken at bedtime.

Child dose

Adjunctive therapy in children aged 3 to 12 years: Day 1: Administer 10 mg/kg body weight of gabapentin Adjunctive therapy in children aged 3 to 12 years: Day 2: Administer 20 mg/kg body weight of gabapentin Adjunctive therapy in children aged 3 to 12 years: From Day 3: Administer 30 mg/kg body weight of gabapentin Adjunctive therapy in children aged 3 to 12 years: The dose may be increased, if needed, to a maximum of 40 mg per kg body weight daily. The total daily dose should be divided into 3 doses.

This medication is used for treating epilepsy and may increase the risk of suicidal thoughts or behaviors, so patients and caregivers should closely monitor for changes in mood or behavior. Suddenly stopping medication can lead to worsening seizures or status epilepticus; therefore, it should be gradually discontinued under a doctor's guidance. Animal studies have reported a possibility of cancer occurrence, but there is currently no clear evidence that this drug causes cancer in humans. Sudden and unforeseen death cases have been reported during the use of this medication, particularly in epilepsy patients, who should receive regular monitoring from healthcare professionals. If severe pancreatitis symptoms, such as hemorrhagic pancreatitis, occur, the medication should be discontinued immediately and healthcare consultation should be sought. Children aged 3 to 12 years may experience neuropsychiatric adverse reactions, including emotional instability, hostility, thought abnormalities, and hyperactivity, necessitating vigilance. Taking this medication with central nervous system depressants, including narcotics, can lead to severe drowsiness, respiratory depression, coma, and risk of death, so the decision to co-administer should be carefully determined by a physician. Patients with allergies to this drug or its ingredients, acute pancreatitis, certain types of seizures, or lactose intolerance should not use this medication. Caution should be exercised when administering this drug to patients with reduced renal function, the elderly, those with a history of psychosis, pregnant or breastfeeding individuals, and children with attention deficit or behavioral disorders, requiring regular monitoring. Various side effects, such as dizziness, drowsiness, ataxia, nausea, vomiting, weight gain, and visual disturbances may occur; report any abnormal symptoms to healthcare professionals immediately. During pregnancy, this medication may affect the fetus; consult a doctor if planning to conceive or if pregnant, and take caution during breastfeeding. This medication may impair the ability to drive or operate machinery, so it is safe to avoid these activities at the start of treatment. In case of overdose, symptoms such as dizziness, drowsiness, and coma may occur, so it's crucial to adhere strictly to the prescribed dosage regimen and seek medical attention if any adverse reactions occur. Store this medication out of reach of children, and keep it in its original container to prevent misuse or quality degradation.

• Suicidal ideation
• suicidal behavior
• depression
• emotional instability
• hostility
• thought disorders
• hyperactivity
• abdominal pain
• back pain
• fatigue

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is safe to store it at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the drug's efficacy and prevent deterioration.

Appearance

White hard capsule containing white or grayish-white powder

Package unit

30 capsules/bottle, 300 capsules/bottle